The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 01 04 2019
accepted: 07 04 2019
entrez: 5 6 2019
pubmed: 5 6 2019
medline: 7 3 2020
Statut: ppublish

Résumé

Complement activation generates the core effector protein C5a, a potent immune molecule that is linked to multiple inflammatory diseases. Two C5a receptors, C5aR1 (C5aR, CD88) and C5aR2 (C5L2, GPR77), mediate the biological activities of C5a. Although C5aR1 has broadly acknowledged proinflammatory roles, C5aR2 remains at the center of controversy, with existing findings supporting both immune-activating and immune-dampening functions. Recent progress has been made toward resolving these issues. Instead of being a pure recycler and sequester of C5a, C5aR2 is capable of mediating its own set of signaling events and through these events exerting significant immunomodulatory effects not only toward C5aR1 but also other pattern recognition receptors and innate immune systems, such as NLRP3 inflammasomes. This review highlights the existing knowns and unknowns concerning C5aR2 and provides a timely update on recent breakthroughs which are expected to have a substantial impact on future fundamental and translational C5aR2 research.

Identifiants

pubmed: 31160390
pii: 202/12/3339
doi: 10.4049/jimmunol.1900371
doi:

Substances chimiques

C5aR2 protein, human 0
Inflammasomes 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
Receptor, Anaphylatoxin C5a 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3339-3348

Informations de copyright

Copyright © 2019 by The American Association of Immunologists, Inc.

Auteurs

Xaria X Li (XX)

School of Biomedical Sciences, The University of Queensland, St. Lucia, Queensland 4072, Australia; and.

John D Lee (JD)

School of Biomedical Sciences, The University of Queensland, St. Lucia, Queensland 4072, Australia; and.

Claudia Kemper (C)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.

Trent M Woodruff (TM)

School of Biomedical Sciences, The University of Queensland, St. Lucia, Queensland 4072, Australia; and t.woodruff@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH